Cargando…

Real‐world evaluation of ocrelizumab in multiple sclerosis: A systematic review

Across its clinical development program, ocrelizumab demonstrated efficacy in improving clinical outcomes in multiple sclerosis, including annualized relapse rates and confirmed disability progression. However, as with any new treatment, it was unclear how this efficacy would translate into real‐wor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Montalban, Xavier, Matthews, Paul M., Simpson, Alex, Petrie, John L., Sammon, Cormac, Ramagopalan, Sreeram, Disanto, Giulio, Kuhle, Jens
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10014013/ https://www.ncbi.nlm.nih.gov/pubmed/36728340 http://dx.doi.org/10.1002/acn3.51732

Ejemplares similares

Can real-world data really replace randomised clinical trials?
por: Ramagopalan, Sreeram V., et al.
Publicado: (2020)

Increasing cancer risk over calendar year in people with multiple sclerosis: a case–control study
por: Zecca, Chiara, et al.
Publicado: (2020)

Ocrelizumab: a new milestone in multiple sclerosis therapy
por: Mulero, Patricia, et al.
Publicado: (2018)

Real-world experience of ocrelizumab in multiple sclerosis in an Arab population
por: Garcia-Cañibano, Beatriz, et al.
Publicado: (2021)

Estimating the proportion of variation in susceptibility to multiple sclerosis captured by common SNPs
por: Watson, Corey T., et al.
Publicado: (2012)

Derivation of DO-BITS, a score for predicting success on Love Island: a retrospective, observational cohort study
por: Simpson, Alex, et al.
Publicado: (2020)

Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis
por: Daniels, K., et al.
Publicado: (2020)

Ocrelizumab in Multiple Sclerosis: A Real-World Study From Spain
por: Sempere, Angel P., et al.
Publicado: (2021)

Real‐world experience of ocrelizumab in multiple sclerosis in a Spanish population
por: Fernandez‐Diaz, Eva, et al.
Publicado: (2020)

Real-world experience of ocrelizumab in multiple sclerosis patients in Latin America
por: ROJAS, Juan Ignacio, et al.
Publicado: (2021)

Smoking and Multiple Sclerosis: An Updated Meta-Analysis
por: Handel, Adam E., et al.
Publicado: (2011)

Exploring the effect of vitamin D(3) supplementation on the anti-EBV antibody response in relapsing-remitting multiple sclerosis
por: Rolf, Linda, et al.
Publicado: (2017)

The use of UK primary care databases in health technology assessments carried out by the National Institute for health and care excellence (NICE)
por: Leahy, Thomas P., et al.
Publicado: (2020)

Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis
por: Turner, Benjamin, et al.
Publicado: (2019)

Protein-Protein Interaction Analysis Highlights Additional Loci of Interest for Multiple Sclerosis
por: Ragnedda, Giammario, et al.
Publicado: (2012)

An Updated Meta-Analysis of Risk of Multiple Sclerosis following Infectious Mononucleosis
por: Handel, Adam E., et al.
Publicado: (2010)

Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis
por: Hauser, Stephen L., et al.
Publicado: (2021)

R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 10
por: Simpson, Alex, et al.
Publicado: (2022)

Genomic Regions Associated with Multiple Sclerosis Are Active in B Cells
por: Disanto, Giulio, et al.
Publicado: (2012)

Under-recording of hospital bleeding events in UK primary care: a linked Clinical Practice Research Datalink and Hospital Episode Statistics study
por: McDonald, Laura, et al.
Publicado: (2018)

Prognostic Markers of Ocrelizumab Effectiveness in Multiple Sclerosis: A Real World Observational Multicenter Study
por: Lanzillo, Roberta, et al.
Publicado: (2022)

Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY)
por: Chisari, Clara G., et al.
Publicado: (2023)

Ocrelizumab: A Review in Multiple Sclerosis
por: Lamb, Yvette N.
Publicado: (2022)

Association of Pertuzumab, Trastuzumab, and Docetaxel Combination Therapy With Overall Survival in Patients With Metastatic Breast Cancer
por: Ramagopalan, Sreeram V., et al.
Publicado: (2021)

The Refinement of Genetic Predictors of Multiple Sclerosis
por: Disanto, Giulio, et al.
Publicado: (2014)

Multiple Sclerosis
por: Ramagopalan, Sreeram, et al.
Publicado: (2011)

Comparative effectiveness of natalizumab versus ocrelizumab in multiple sclerosis: a real-world propensity score–matched study
por: Pape, Katrin, et al.
Publicado: (2022)

Vitamin D receptor binding, chromatin states and association with multiple sclerosis
por: Disanto, Giulio, et al.
Publicado: (2012)

What is Next for the Genetics of Multiple Sclerosis?
por: Ramagopalan, Sreeram V., et al.
Publicado: (2011)

The value of innovation: association between improvements in survival of advanced and metastatic non-small cell lung cancer and targeted and immunotherapy
por: Ramagopalan, Sreeram, et al.
Publicado: (2021)

Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension
por: Hauser, Stephen L., et al.
Publicado: (2020)

Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis
por: Cellerino, Maria, et al.
Publicado: (2021)

Multiple sclerosis: major histocompatibility complexity and antigen presentation
por: Ramagopalan, Sreeram V, et al.
Publicado: (2009)

Safety and patient experience with at‐home infusion of ocrelizumab for multiple sclerosis
por: Barrera, Britney, et al.
Publicado: (2023)

Decrease in rate of multiple sclerosis-related hospitalizations in Portugal
por: Pereira, Marta, et al.
Publicado: (2016)

COVID-19 in ocrelizumab-treated people with multiple sclerosis
por: Hughes, Richard, et al.
Publicado: (2021)

Ocrelizumab for the Treatment of Multiple Sclerosis: Safety, Efficacy, and Pharmacology
por: Mancinelli, Chiara Rosa, et al.
Publicado: (2021)

Pregnancy outcome following exposure to ocrelizumab in multiple sclerosis
por: Chey, Shin Yee, et al.
Publicado: (2022)

Acute Effects of Ocrelizumab Infusion in Multiple Sclerosis Patients
por: Akgün, Katja, et al.
Publicado: (2022)

An overview of pivotal trials and real-world evidence for CD20-depleting therapy in multiple sclerosis: Immunotherapy with rituximab, ocrelizumab, and ofatumumab
por: Ovchinnikov, Arkady, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ud8ni21vm4d0jccc84vgass05d